scm logo

SCM Life Science (SCM Life Science, KOSDAQ 298060, CEO Lee Byung-gun), a company specializing in cell therapy, has signed a contract with Cha Biotech (CEO Oh Sang-hoon) to complete a bone marrow-derived cell therapy product cmo (contract manufacturing organization). 

With this contract, Cha Biotech will produce "SCM-AGH" and "SCM-CGH" items under development by SCM Life Science through its subsidiary Cha Bio Lab pharmaceutical manufacturing facility. The contract for consignment production is likely to expand to commercial products to be released in the future.

The item is a highly likely treatment to be approved after phase 2 clinical trials after receiving "designation of rare drugs in the development stage" from the Ministry of Food and Drug Safety for chronic transplant host disease (SCM-CGH) and phase 2a clinical trials.

SCM Life Science uses Cha Biotech's excellent facilities to increase synergy between the two companies before expanding its own commercial GMP facilities and the contract was meant to show that the cooperative model between domestic companies can also help increase global competitiveness. It also plans to use Coimunee's secret in operating cGMP production facilities in the United States.

Lee Byung-gun, CEO of Scm Life Science, said, "There is a GMP facility that has obtained approval for the manufacturing of high-tech biopharmaceuticals on its own, but we hope that we can cooperate with Cha Biotech to complete the ongoing clinical trial and speed up the launch of the product through conditional approval." , “We will be able to produce high-quality products based on Cha Biotech's know-how in developing stem cell treatments and its ability to operate GMP production facilities”

Oh Sang-hoon, CEO of Cha Biotech, said, "With this contract, we plan to expand strategic cooperation in the entire process from clinical trials of Scm Life Science and stem cell therapy to product production." and “We will actively support the development of cell therapy products promoted by Scm Life Science by utilizing CHA Biotech’s capabilities and CHA Bio Group’s industry, academia, research and disease system.”.

Cha Biotech is leading the global cell gene medicine CDMO business. In December 2020, its subsidiary Cha Bio Lab acquired the first high-tech bio-medicine manufacturing license in Korea, laying the foundation for accelerating the global CDMO business.

In February, the US subsidiary Mattica Bio started construction of a cGMP facility with global-level manufacturing facilities in Texas. Cha Biotech plans to target the CDMO market for cell gene therapy in the U.S., Europe, and Asia in connection with the second Pangyo Techno Valley GMP facility, which will be completed in 2024, after accumulating CDMO business experience and technology through Matica Bio.